PARAMUS, N.J., Jan. 10, 2013 /PRNewswire/ -- Proteonomix, Inc. (the "Company") (OTC Pink: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that upon its name change to StromaCel, Inc., presently scheduled for January 18, 2013, all shareholders will be required to submit their stock certificates to our transfer agent, VStock Transfer, in order to obtain their new share certificates in the Company.
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. StromaCel, our subsidiary, develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. National Stem Cell, Inc. is prosecuting patent applications licensed to it.
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
SOURCE Law Offices of Roger L. Fidler